Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies- Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1075
https://www.valueinhealthjournal.com/article/S1098-3015(15)03151-4/fulltext
Title :
Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies- Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03151-4&doi=10.1016/j.jval.2015.09.1075
First page :
A440
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
579